Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previously untreated poor-risk acute myeloid leukemia.

CONCLUSIONS: Selinexor plus 7+3 is a safe regimen for newly diagnosed poor-risk AML patients and warrants further investigation in a larger clinical trial.
PMID: 31636097 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - October 20, 2019 Category: Cancer & Oncology Authors: Sweet K, Komrokji RS, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE Tags: Clin Cancer Res Source Type: research